Author

B. Papke

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Assay:imaging· 1 Assay:metabolomics· 1 Organism:mouse· 1

Frequent Co-Authors

A. D. Cox· 2 shared C. J. Der· 2 shared A. E. D. Van Swearingen· 1 shared A. Y. Feng· 1 shared B. Mundt· 1 shared C. Gutierrez-Ford· 1 shared C. V. Pecot· 1 shared D. R. Blake· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. D. Cox

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition

T. Isermann, K. L. Schneider, F. Wegwitz, T. De Oliveira, L.-C. Conradi, V. Volk, F. Feuerhake, B. Papke, S. Stintzing, B. Mundt, F. Kuehnel, U. M. Moll, R. Schulz-Heddergott

This study shows that combining HSP90 inhibitors with p53 activation or CDK4/6 inhibition enhances colorectal cancer therapy by disrupting the HSF1-HSR feedback loop.

bioRxiv · Feb 22, 2024Cancer Biology

Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancer

J. N. Diehl, J. E. Klomp, K. R. Snare, D. R. Blake, P. S. Hibshman, Z. D. Kaiser, T. S. K. Gilbert, E. Baldelli, M. Pierobon, B. Papke, R. Yang, R. G. Hodge, N. U. Rashid, E. F. Petricoin, L. E. Herring, , C. J. Der

This study identifies upregulated and downregulated kinases in KRAS-mutant pancreatic cancer using chemical proteomics, revealing potential therapeutic targets.

bioRxiv · Apr 27, 2021 · PreprintCancer Biology

Silencing of oncogenic KRAS by mutant-selective small interfering RNA

B. Papke, S. H. Azam, A. Y. Feng, A. E. D. Van Swearingen, C. Gutierrez-Ford, P. S. Pallan, M. Egli, A. D. Cox, C. J. Der, C. V. Pecot

This study develops a mutant-selective siRNA, EFTX-D1, that targets KRAS mutations in codons 12 and 13, reducing mutant KRAS expression and impairing cancer cell proliferation.

bioRxiv · Oct 8, 2020Cancer Biology